National Life Sciences Capital Allocation 2026

Editorial and financing review: October 1, 2026. Operating figures retain their stated provider, geography and reporting period. A later review date does not make an earlier observation current.

Key takeaway

Life-sciences demand remains concentrated in established clusters and funded users, while broad vacancy and concessions constrain speculative laboratories. Newer buildings and tenant-specific manufacturing facilities can perform differently from obsolete lab stock.

Require tenant cash runway, signed commitments, building suitability and enough capital for a long lease-up. September’s financing reset increases holding costs; venture funding or a cluster ranking does not establish rentable demand or development feasibility.

Financing assumptions

The Fed raised its target to 3.75%–4.00% on September 16. The September 30 Treasury close was 5.29% for the 10-year and 5.64% for the 30-year. Source: Federal Reserve FOMC Statement September 16 2026; Source: U.S. Treasury Daily Par Yield Curve September 2026.

Size debt from achieved income and include capital work and carrying reserves. Test a higher borrowing cost, slower stabilization and a wider exit cap rate; improve rent, proceeds or exit assumptions only when property evidence and lender terms support them. See U.S. Commercial Real Estate Outlook Q4 2026 for the common macro scenarios.

Evidence carried forward

The following source-period observations and earlier qualifications remain part of the research record. Current allocation and financing conclusions are stated above.

Source: Cushman & Wakefield San Diego Life Sciences MarketBeat Q2 2026 replaces the broad San Diego inflection watch with table-grade evidence: 26.9% vacancy, -477,995 SF YTD absorption, about 30.2% availability, $5.59/SF/month NNN rent, and a 1.27M-SF pipeline that was 70.3% preleased. Torrey Pines remained the premium node at 13.3% vacancy and positive Q2 absorption, while Sorrento Mesa was 39.9% vacant. San Diego stays a Tier 1 cluster allocation, but only through premium nodes, preleased build-to-suits, or distressed basis—not broad lab beta.

Structured evidence scope: references below to the legacy structured snapshot describe earlier recorded rows or gaps. Supabase/Postgres is authoritative. This editorial review did not rerun those database counts or imports; verify current row custody, period and source before using them in underwriting.

Question

How should capital allocate across U.S. life sciences real estate in 2026 given the post-2022 vacancy reset, the hypothesized shift from lab-office toward cGMP / validated production environments, and the widening gap between established clusters and emerging Texas nodes?

Supporting detail

The Source Collection: CBRE Insights Market Reports Public Crawl 2026 adds review-level support to that allocation frame. Its life-sciences rows reinforce reset conditions and pipeline contraction, while the medical-outpatient rows belong more to healthcare real estate diligence than lab-office allocation. Because this is a small cluster and several rows still need source checks or normalization, it should update the page's caveats rather than override the existing DB-backed Boston / San Diego / Raleigh-Durham comparison.

Source: JLL 2026 U.S. Lab Property Report now preserves JLL's own public report page behind the earlier secondary lab-availability signal. The visible JLL body supports a bottoming / early-recovery read, but not a broad risk-on allocation: availability has started contracting after peaking in 2025, demand is rebounding in key markets, flight-to-quality is accelerating, and elevated supply still pressures rents and leasing behavior. Keep this separate from MOB / outpatient medical facility evidence and from table-grade C&W, CBRE, and Transwestern source-family rows.

The June 2026 GlobeSt metadata captures add a narrower public-description layer to the same watch item. GlobeSt described lab availability as contracting after the correction while still noting tenant-friendly conditions from the prior development surge, and separately described San Diego as seeing its best venture-capital pace since 2021 with positive first-quarter absorption despite high availability. Because the captures expose metadata and descriptions rather than full article bodies, use them as directional flags only; they should not overwrite the DB-backed Q3/Q4 2025 vacancy and pipeline metrics. See Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026 and Source: GlobeSt San Diego Life Sciences VC Pace 2026.

Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026 adds the first current source-preserved C&W national table to this allocation page. It confirms that the 2026 setup is still a reset, not a broad beta recovery: U.S. vacancy was 23.6%, asking rent was down 3.4% year over year, and Q1 absorption was essentially flat. The investable improvement is supply and capital-formation based: deliveries slowed sharply, 72% of the under-construction pipeline was build-to-suit, sublease vacancy declined slightly, VC funding improved to $8.0B, and IPO activity strengthened.

Source: CBRE Q1 2026 U.S. Life Sciences Figures triangulates the same reset with a different denominator. CBRE's top-13 lab/R&D summary reported 23.2% vacancy, negative absorption across nine of 13 major markets totaling 1.2M SF, $67.30/SF average NNN rent, 4.7M SF under construction, and $7.4B of Q1 VC funding. The allocation implication is unchanged but sharper: improving biotech capital formation is not enough by itself. Broad lab-office exposure still needs a rent / downtime / tenant-credit discount, while new-money deployment should favor cluster depth, validated production, BTS credit, or basis resets rather than generic beta.

Source: Transwestern U.S. Market Life Sciences Q1 2026 adds a third Q1 2026 source-family read. Its qualified-inventory denominator reported 275.9M SF of U.S. inventory, 13.5% direct vacancy, -462,974 SF of Q1 net absorption, $53.50/SF NNN asking rent, and 13.4M SF under construction. That does not overturn the reset thesis because the same report shows negative current-quarter absorption and uneven market performance; it instead tightens the denominator warning and adds a first structured Houston row for Texas life-sciences diligence.

Source: CBRE 2026 U.S. Life Sciences Trends adds the forward-looking CBRE outlook companion to the Q1 figures. It supports the page's basis-and-cluster posture by saying demand has stabilized, lab / R&D construction is projected to hit a 10-year low, capital is re-engaging, and transaction activity may gain momentum in key markets as policy uncertainty and financing conditions improve. That is a watchlist and entry-timing signal, not a broad upgrade for all lab-office inventory.

Source: Colliers Life Sciences Market Outlook 2026 adds the Colliers qualitative version of the same disciplined-growth thesis. The public landing page says venture capital has normalized, speculative construction has slowed, tenant demand is focusing on premier lab environments in leading innovation hubs, and Boston, San Francisco, and San Diego continue to attract institutional capital and top-tier tenants despite elevated vacancy in select secondary markets. Because the full report download was not directly retrievable during intake, use this as source-family confirmation of cluster selectivity and supply moderation, not as a numeric ranking, vacancy, rent, absorption, pipeline, or VC dataset.

Source: Cushman & Wakefield Raleigh-Durham Life Sciences MarketBeat Q1 2026 adds the local RTP / Triangle source-family package behind the national C&W Raleigh-Durham row. It improves the local read: vacancy declined to 27.6%, absorption rebounded to +142,352 SF, construction stayed at 0 SF, and the RTP / I-40 corridor carried most inventory and all positive absorption. It also creates a source-family caveat because the local PDF reports 73,306 SF of new leasing activity, while the earlier national import carried a different Raleigh-Durham leasing figure from the national table package.

The allocation split is explicit: Boston and San Diego have the deepest cluster proof but still need submarket and basis discipline; Raleigh-Durham is a reset-market opportunity because vacancy is high while new supply has stopped; Philadelphia and selected low-vacancy markets deserve follow-up diligence under C&W's source family; Texas is earlier-stage coverage where institutional anchors matter but the source layer does not yet support broad market-rate lab deployment.

Source: Cushman & Wakefield Life Sciences Labor Dynamics Across Key U.S. Markets 2026 adds a location gate that should sit alongside vacancy, pipeline, and venture-capital analysis. The report's labor comparison supports the depth of Boston-Cambridge, the Bay Area, San Diego, and Raleigh-Durham, but also makes the wage burden of the coastal hubs explicit. Denver-Boulder and Chicago are useful cost-to-talent comparators, while Raleigh-Durham combines a meaningful employer and university ecosystem with a less expensive labor profile than the highest-cost clusters. Site selection should therefore test specialized labor supply, hiring demand, wage competitiveness, education pipelines, cost of living, and quality of life before treating a cluster label as tenant-demand proof. Inputs are mostly 2024 employment, wage, and education data plus 2025 job-posting demand; the report's indexes are directional and do not substitute for local labor or property-market diligence.

Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q2 2026 updates the national reset with a more difficult operating quarter: -1.4M SF of absorption, $64.17/SF asking rent down 5.3% year over year, and 24.3% vacancy, even as new leasing rose 8% to 1.7M SF. The supply signal is more constructive: no new deliveries across the 12 tracked markets in Q2 and 72% of the 4.5M SF expected 2026 deliveries already preleased. Capital formation improved through $9.2B of Q2 venture funding, but R&D sales fell 24% to $1.3B even as pricing rose 7%. Keep this as a source-family update to the reset thesis: favor preleased/BTS and later-stage tenant exposure while stress-testing speculative lab downtime and rent recovery.

Source: Cushman & Wakefield UK Life Science Marketbeat Q2 2026 provides a cross-border comparator without changing the U.S. allocation buckets. In London's, Cambridge's, and Oxford's Golden Triangle, Q2 take-up was 175,000 SF—below the five-year quarterly average—while 779,200 SF was under offer and 2.9M SF remained under construction with only 20% pre-let or under offer. Quoting rents were stable but achieved rents remained under pressure, and a £2.005B UK VC quarter was dominated by one £1.551B Isomorphic Labs round. The underwriting lesson travels: stronger biotech funding and a visible under-offer pipeline do not equal stabilized absorption or rent recovery. Stress achieved rents, lease-up, lab fit-out, tenant funding, and exit yields separately, and distinguish established ecosystems from speculative supply.

Source: CBRE European Life Sciences Ecosystems adds a dated European ecosystem-depth baseline behind the current Golden Triangle comparison. CBRE's 2024 deck profiles ten cities using mostly 2021–2023 evidence: London represented 48% of UK life-sciences VC in 2023 (£1.29B), Cambridge recorded £564M, Basel was anchored by Roche and Novartis with approximately 1.5M SF of mixed-use R&D planned by 2030, and Paris had only 2.9M SF of purpose-built lab/R&D space excluding owner-occupiers. These figures are historical and heterogeneous, but they sharpen the location gate: university, pharma, VC, incubator, and specialized-lab depth can support tenant formation without removing current vacancy, fit-out, lease-up, or funding-cycle risk. Refresh the city-level inputs with current marketbeat evidence before using them in allocation or valuation.

Source: CBRE Boston Metro Life Science Figures Q1 2026 adds the current Boston-specific CBRE source-family row. Greater Boston lab availability held at 32.7%, vacancy was 27.9%, Q1 absorption was still negative at -117,186 SF, and cumulative negative absorption since Q1 2025 exceeded 1.1M SF. That is marginally better than Q4 2025 absorption but not a broad recovery signal; it reinforces the page's view that Boston remains Tier 1 by cluster depth while generic lab-office exposure still needs basis, downtime, tenant-credit, and submarket controls.

Source: Lundbeck Announces Greater Boston Innovation Hub 2026 adds a September 2026 company-specific cluster signal: Lundbeck plans to relocate its U.S. headquarters from Deerfield, Illinois, and establish a Greater Boston innovation hub over the next year. It reinforces Boston's strategic draw for neuroscience R&D and collaboration, but Lundbeck named no site, lease, area, or delivery. Do not convert the announcement into lab demand square footage, absorption, or a recovery call until property-level execution is visible.

Source: CBRE New York City Life Sciences Figures Q1 2026 adds a New York-specific CBRE source-family row. The visible page shows weak current demand rather than a scaled deployment market: 27,000 SF of Q1 leasing velocity, 27.5% lab-exclusive availability, $96.43/SF lab-exclusive asking rent, and $263.65M of quarterly VC funding. NYC belongs in the Northeast watchlist / peer-comparison set, but this source does not justify moving it into the main allocation buckets without inventory, pipeline, tenant-depth, and submarket proof.

Source: CBRE Denver/Boulder Life Sciences Figures Q1 2026 adds a smaller Front Range comparator. Denver/Boulder showed 85,000 SF of Q1 leasing activity, 282,000 SF of rolling four-quarter leasing, 12.7% direct vacancy, 18.4% Boulder vacancy, $205M of Q1 VC funding, and only 221,000 SF in the pipeline. That supports an emerging-cluster watchlist lane: better current vacancy than the loose coastal reset markets, but still too thin for broad institutional allocation without inventory, rent, tenant-credit, and submarket proof.

Source: CBRE Puget Sound Life Science Figures H2 2025 adds Seattle as a CBRE source-family watchlist cluster rather than a pure intuition node. Puget Sound screened at 21.2% total vacancy, -97,208 SF of 2025 net absorption, and 39.0% investor-owned availability, while Bothell, South Lake Union, and Bellevue / Wilburton provide concrete node evidence. The allocation implication is specialist and selective: Seattle can belong in a second-tier cluster monitor, but broad lab-office capital still needs tenant credit, lease economics, and basis proof.

Allocation Frame

What The Market Is Really Saying

• The 2021-2022 lab boom is over. Vacancy is now high enough in Boston, San Diego, and Raleigh-Durham that no market should be underwritten as if lab demand is still supply-constrained across the board.
• Cluster strength still matters more than cheapness. Boston and San Diego remain the two strongest deployable clusters in this source set because tenant density, research anchors, and regulatory stickiness are real even while the market is resetting. Boston / Cambridge has the global biotech depth and capital ecosystem; San Diego has a West Coast biology cluster with sharper submarket dispersion between Torrey Pines / UTC and Sorrento Mesa / Sorrento Valley.
• Pipeline shutoff matters. Raleigh-Durham's most important number is not just 32.3% vacancy; it is 0 SF under construction. That is what makes the market interesting for capital willing to buy through the reset.
• Texas is a strategic option on future depth, not yet a proven broad allocation market. The source trail is strong on campus formation and institutional anchors, but weak on rents, vacancy, and transaction evidence compared with Boston, San Diego, and RTP.
• South San Francisco now has a standalone draft geography node, but it is still intentionally not given its own bucket here because the source layer remains thinner than Boston, San Diego, and RTP and does not yet support a comparably defensible allocation call.

Best-Fit Capital By Market

• Boston is best for capital that wants the deepest global biotech cluster and can be patient on lease-up. It is weakest for investors who need near-term mark-to-market rent momentum.
• San Diego is best for capital that can distinguish Torrey Pines and UTC from Sorrento Mesa's larger spec overhang. It is weaker for buyers treating the whole market as one uniform lab corridor.
• Raleigh-Durham is best for opportunistic investors who want a real life sciences ecosystem without paying Boston or San Diego basis. It is weaker for investors who require a currently tight market rather than a reset market.
• Houston works for strategic capital that believes institutional healthcare and research anchors can compound into a real life sciences district around TMC. It is weaker for anyone pretending Houston already has the same depth as the coastal clusters.
• Dallas works for early thematic capital that values Pegasus Park's incubator-to-graduation pathway. It is weakest for large capital that needs immediate market depth and a fully formed tenant base.

The 2026 Split: Lab-Office Versus cGMP

The most important underwriting hypothesis is that demand is moving away from speculative lab-office as a generic venture-growth trade and toward cGMP manufacturing and validated production environments. The source trail supports this as a strategic direction, but the legacy structured snapshot does not yet distinguish lab-office from cGMP / manufacturing space, so the shift should be treated as a diligence thesis rather than a quantified market fact. That changes the allocation map:

• Boston and San Diego remain the primary R&D cluster markets, but broad office-like lab supply is still working through excess inventory.
• Raleigh-Durham looks more interesting today as a value and conversion market because its construction pipeline has already shut down.
• Houston and Dallas are more attractive as future manufacturing and institutional-anchor stories than as current pure-play lab-office markets, but they remain provisional qualitative nodes until market-rate vacancy, rent, absorption, and transaction data are preserved.

Hillsboro adds a grounded biomanufacturing example to this shift: Genentech began construction on a reported $750 million, 211,000-square-foot manufacturing expansion, with operations planned for 2031. Company and state releases distinguish approximately 250 manufacturing jobs from 200 construction jobs; the state combines them as approximately 450 total. This is a project-level cGMP and device fill-finish commitment, not a life-sciences market vacancy, rent, or absorption series. See Genentech Hillsboro Manufacturing Expansion and Source: Genentech Hillsboro Manufacturing Expansion Groundbreaking 2026.

Roche Genentech's Boston innovation center adds an operating R&D anchor in Allston: Roche reports a 95,000-SF, 10-year lease and a September 2026 opening at Harvard's Enterprise Research Campus. Its 2025 launch announcement had described an initial 30,000-SF lease, but the sources do not reconcile the area change. This is tenant-specific demand inside a soft Boston lab market, not an absorption series or broad recovery signal. See Roche Genentech Innovation Center Boston and Source: Roche Genentech Innovation Center Boston Opening.

What Not To Do

• Do not treat high vacancy in Boston or San Diego as proof that the cluster thesis broke. The source trail points to a supply-cycle reset, not a collapse in scientific relevance.
• Do not treat Texas campus formation as proof that Houston or Dallas are already scaled life sciences markets. The repo's Texas source note is explicit that the boom is "not quite there yet."
• Do not underwrite generic flex or office product as interchangeable with real life sciences space. Regulatory stickiness, MEP intensity, and TI reload risk still define the asset class.

Why This Node Matters

This is the first national allocation note in the graph for a specialized asset class that already has both an underwriting page and a geography page. It turns Life Sciences and Lab Underwriting and Life Sciences Cluster Geography into a capital-deployment decision rather than leaving them as parallel reference pages.

The reported Long Island City lab sale at a loss—Longfellow sold the building for $6M less than its prior purchase price before redevelopment—adds a basis-reset warning to the life-sciences capital screen. It supports underwriting conversion and lab-repositioning risk explicitly, but the source does not disclose the asset's occupancy, lab specifications, cap rate, or realized loss percentage; it is not a marketwide valuation index. See Source: Long Island City Lab Sells At A Loss: The N.Y. Deal Sheet.

Recorded structured evidence

All figures sourced from the legacy structured snapshot market_observations. Geography filter: property_type = 'Life Sciences' or name LIKE '%Life%'. Sources: Hunneman / C&W / Colliers / Lincoln LPC (Boston); C&W / Savills / Newmark / CBRE (San Diego); C&W (Raleigh-Durham).

Boston / Greater Boston Life Sciences

San Diego Life Sciences

Submarket vacancy (Q3 2025, C&W): Torrey Pines 10.2% on 6.2M SF (tightest), UTC/Campus Point 16.6% on 3.6M SF, Sorrento Mesa 39.7% on 7.6M SF (highest), Sorrento Valley 38.0% on 1.6M SF.

Note: Savills flagged ~5 former Pfizer buildings expected to hit the market, potentially pushing wet lab availability to ~45%.

Raleigh-Durham / RTP Life Sciences

The pipeline-shutoff metric remains Raleigh-Durham's most important structural signal: 0 SF under construction as of Q1 2026 means no new dilutive supply is coming even as vacancy remains high. The local C&W report is also a submarket warning, because RTP / I-40 carries most of the inventory and positive absorption while Southern Wake County remains a high-vacancy small-base row.

Houston / Texas Life Sciences

The DB now contains a Transwestern Q1 2026 source-family baseline for Houston life sciences, but not a Texas Medical Center-specific or Dallas life-sciences market-rate series. Houston should therefore move from "no structured observations" to "thin structured baseline": useful enough for a vacancy / rent / absorption check, not enough to underwrite broad Texas institutional deployment.

C&W Q1 2026 National Life Sciences Table

market_import_cw_us_life_sciences_marketbeat_q1_2026 adds C&W source-family rows for the national market and 12 reported markets. The national row now preserves 239.5M SF of inventory, 23.6% vacancy, $65.48/SF weighted asking rent, -23,659 SF of Q1 absorption, 1.18M SF of Q1 deliveries, 5.35M SF under construction, 72% BTS pipeline share, $2.1B of R&D property sales, $8.0B of venture funding, and eight IPOs raising more than $2.3B. Market rows add C&W-labeled vacancy, asking rent, absorption, leasing, inventory, deliveries, and under-construction observations for Boston, Chicago, Denver, Los Angeles-Orange County, New Jersey, New York City, Philadelphia, Raleigh-Durham, San Diego, San Francisco Bay Area, Seattle, and Suburban Maryland.

CBRE Q1 2026 Top-13 Life Sciences Figures

market_import_cbre_us_life_sciences_figures_q1_2026 adds seven CBRE source-family rows from the visible public Q1 2026 U.S. Life Sciences Figures page. The national top-13 lab/R&D row preserves 23.2% vacancy, a 30 bps QoQ vacancy increase, -1.2M SF of negative net absorption across nine of 13 major markets, $67.30/SF average NNN asking rent, 4.7M SF under construction, and $7.4B of Q1 VC funding. A separate Los Angeles row preserves CBRE's 700K SF project-start callout. Use these rows as directional CBRE triangulation against C&W's broader table, not as a same-denominator market replacement.

Transwestern Q1 2026 Qualified Inventory Table

market_import_transwestern_us_life_sciences_q1_2026 adds Transwestern source-family rows for the national market and 11 visible markets. The national row preserves 275.9M SF of inventory, 13.5% direct vacancy, -462,974 SF of Q1 net absorption, 923,499 SF of 12-month net absorption, $53.50/SF NNN asking rent, -3.0% annual asking-rent change, 13.4M SF under construction, $7.1B of Q1 venture funding across 101 deals, six IPOs raising $1.6B, and $7.15B of 2026 YTD NIH distributions. Market rows add vacancy, rent, absorption, 12-month absorption, inventory, rent-change, and construction observations for Boston, Chicago, Houston, New Jersey, New York, Philadelphia, Raleigh/Durham, Phoenix, San Diego, San Francisco, and Washington DC.

Gaps

• Dallas life sciences market data: Dallas still has no vacancy, rent, or absorption observations in the DB. Houston now has a Transwestern source-family baseline, but no Texas Medical Center-specific or Dallas market-rate series. Texas allocation calls remain provisional relative to Boston, San Diego, Raleigh-Durham, and other table-backed markets.
• South San Francisco: A standalone corridor page now exists, but there are still no South-San-Francisco-specific observations in the DB. The current public evidence is mainly city cluster data plus San Mateo County proxy metrics, which is enough for geography routing but not for a standalone allocation bucket.
• Boston submarket breakdown: Cambridge is tracked separately in the DB, but other Boston-area submarkets (Route 128 corridor, Seaport, Waltham) have no individual geography entries. The metro vacancy divergence between Cambridge (12.7%) and the broader metro (28.8%) is notable but incompletely characterized.
• Capital markets / transaction data: C&W now provides a national $2.1B Q1 2026 R&D property sales-volume observation, but no market-level investment sales volume, cap rate, or price-per-SF observations exist in the DB. The basis-reset thesis for Boston and San Diego still cannot be quantified from current structured market-level data.
• cGMP and manufacturing space: The DB does not distinguish lab-office from cGMP/manufacturing space in any of the tracked markets. The allocation note's cGMP argument is a source-supported strategic hypothesis, not a quantified market series.
• Raleigh-Durham — Q3/Q4 2025 update: The most recent RTP observations are as of Q2 2025. No Q3 or Q4 2025 C&W or CBRE report has been imported yet.

Phased Leasing and Lab-Demand Rollover

Kilroy's Oyster Point second phase was reported as half-leased while the REIT navigated soft lab demand, with approximately 1M SF of lease expirations flagged for the following year and most expirations in late 2027. The case supports explicit phase-by-phase leasing and rollover underwriting in life sciences; project completion alone is not demand proof. Source: Oyster Point's Second Phase Half-Leased As Kilroy Navigates Soft Lab Demand

Tenant Growth at a Houston Life-Sciences Campus

Cerenome reportedly tripled its space at Hines' Levit Green life-sciences campus in Houston. Tenant expansion is a qualitative demand signal for specialized clusters and shared infrastructure, but one expansion does not establish market-wide absorption or rent growth. Source: Oncology Company Expands Footprint At Hines' Life Sciences Campus

Revolution Medicines' reported plan to lease approximately 700,000 square feet at Redwood City's Pacific Shores Center adds a larger tenant-growth and reuse example. The biotech company had grown from 61,000 square feet in 2020 to approximately 293,000 square feet before the planned lease, and the space was described as a former Google campus. The signal supports tenant-led absorption and conversion / re-tenanting optionality in an established Bay Area life-sciences node, but the lease plan does not establish execution, rent, occupancy, or a market-wide recovery. Source: New lease on life-sciences? Biotech takes 700K sf at former Google campus in Redwood City

Clinical Lab Tenant at 74M in Somerville

Connect CRE reported that Mass General Brigham leased approximately 100,000 SF at Greystar's 74M for central pathology laboratory services, becoming the building's first tenant. Greystar described the lease as long-term in a separate same-day account, without publishing a numeric term or lease economics. This is healthcare pathology occupancy in a lab building, not biotech R&D demand; it marks property-level tenanting but does not change Greater Boston market vacancy, absorption, or rent evidence. Public project descriptions give 465,000 SF and 469,000 SF for 74M, with no shared measurement basis to reconcile. Source: Mass General Brigham Leases 100K SF at 74M

Related Pages

• Analyses Hub
• Life Sciences Cluster Geography
• Life Sciences and Lab Underwriting
• South San Francisco Life Sciences Corridor
• Boston
• San Diego
• Charlotte and Raleigh-Durham
• Texas Medical Center District
• Dallas-Fort Worth

Sources

• Source: Federal Reserve FOMC Statement September 16 2026

• Source: U.S. Treasury Daily Par Yield Curve September 2026

• Boston Market Intelligence 2025

• San Diego Market Intelligence 2025-2026

• Raleigh-Durham Market Intelligence 2025

• Source: Life Sciences: The Next Frontier for Commercial Real Estate in Texas?

• South San Francisco Life Sciences Cluster 2025-2026

• Source: GlobeSt Life Sciences Recovery After Lab Space Correction 2026

• Source: GlobeSt San Diego Life Sciences VC Pace 2026

• Source: Cushman & Wakefield San Diego Life Sciences MarketBeat Q2 2026

• Source: Cushman & Wakefield U.S. Life Sciences MarketBeat Q1 2026

• Source: CBRE Q1 2026 U.S. Life Sciences Figures

• Source: Transwestern U.S. Market Life Sciences Q1 2026

• Source: JLL 2026 U.S. Lab Property Report

• Source: Lundbeck Announces Greater Boston Innovation Hub 2026

• Source: Mass General Brigham Leases 100K SF at 74M

• Source: Cushman & Wakefield Raleigh-Durham Life Sciences MarketBeat Q1 2026

• Source: Cushman & Wakefield Life Sciences Labor Dynamics Across Key U.S. Markets 2026

Cerenome Levit Green Expansion Scope — August 2026

Source: Oncology Company Expands Footprint At Hines' Life Sciences Campus distinguishes a reported 11,370-SF original lease from a 36,500-SF expanded total, with new fifth-floor laboratory/office fit-out expected Q4 2027. Do not count the total as additional area or assert current expanded occupancy. Phase 1’s reported 290,000 SF and parent 53 acres have different scopes. Primary press text confirms repeated claims through the normal reader; direct original/media access returned 403. Tenant retention/expansion is a cluster-demand input; delayed fit-out, unknown rents/concessions and tenant capital needs challenge an immediate market-wide recovery thesis.

Distinct reported identities Levit Green and Levit Green Phase 1 separate parent acreage, rounded building area and future tenant interior. The reported aggregate Cerenome relationship is applied with total-versus-incremental and future-occupancy qualifications.

Complete reproduced source review, October 11, 2026

Complete October 1 reporting preserves approximately 100,000 SF of announced MGB clinical pathology space at 74M, with actual opening and lease economics unknown. Its 469,000-SF whole-building description stays separate from older 465,000-SF descriptions. One remaining spec suite is not total vacancy or lease-up, and developer demand comments do not establish regional biotech recovery. Current property image provides no measured geometry or current tenant occupancy. Existing separate-source option descriptions retain attribution; historical deleted image identity remains unresolved.

• Source: Connect CRE MGB 74M Complete Lease Review October 1 2026.